A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving ...

Intravenous (IV) compounding safety has garnered recent attention as a result of high-profile incidents, awareness efforts from the safety community, and increasingly ...

Merck (MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND® (fosaprepitant dimeglumine) for ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. EMEND IV contains the active ingredient fosaprepitant dimeglumine.

The approval is primarily based on the phase 3 MK-0517-031 study, in which adding single-dose Emend for injection induced a complete response in nearly 80 percent of patients receiving MEC. The FDA ...